The Daily Papule

Meeting abstracts

AAD 2026

American Academy of Dermatology · Denver, 27–31 March 2026

1,877 abstracts, published in JAAD on 6 July 2026. Their text is on the JAAD website.

  1. 70471

    Lower IL-17A levels in psoriasis patients treated with IL-23 inhibitors versus IL-17 inhibitors

    Minakawa S, Nakagawa J, … senior author Akasaka E

  2. 70840

    Lebrikizumab provides meaningful improvements of absolute endpoints in patients with moderate-to-severe atopic dermatitis in a real-world-setting: interim analysis of the non-interventional study AD-LIFE

    Lauffer F, Gutzmer R, … senior author Thaçi D

  3. 70910

    Medicaid Coverage as a Barrier to Biologic Access for Atopic Dermatitis: A Cross-Sectional Analysis of State Level Variability

    Hemelt S, Fong J, … senior author Culotta N

  4. 71032

    Evaluating Etanercept for the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

    Yoon I, Natarelli N, … senior author Lin A

  5. 71091

    Real-world tildrakizumab effectiveness in the US by biologic experience and geographic region in the PPD CorEvitas Psoriasis Registry

    Lockshin B, Beeghly A, … senior author Prajapati VH

  6. 71092

    Sustained effectiveness of tildrakizumab in patients with moderate-to-severe psoriasis overall and in high-impact areas: 2-year results from the POSITIVE study

    Augustin M, Sommer R, … senior author Mrowietz U

  7. 71101

    Infection Risk Associated With Anifrolumab Versus Traditional Immunosuppressants in Cutaneous Lupus Erythematosus

    Srikumar A, Kang J

  8. 71118

    A questionnaire-based survey to determine knowledge, attitude, and practice of use of rituximab by Indian dermatologists in pemphigus

    De D, Baskaran N, … senior author Handa S

  9. 71145

    A Rare Case of Radiation-Induced Bullous Pemphigoid in Metastatic Merkel Cell Carcinoma Successfully Treated with Dupilumab

    Grandhe N, Romero S, … senior author Durkin J

  10. 71184

    Biologic treatment in Psoriasis and Hidradenitis Suppurativa patients with active malignancy: Experience from a Tertiary Care Hospital

    Carrera Hernandez MJ, Martinez Lorenzo ER, … senior author Gomez Dorado BA

  11. 71226

    Indirect Comparisons of Janus Kinase Inhibitors and Biologic Immunotherapies for Hidradenitis Suppurativa: Results from an Updated Systematic Review and Network Meta-analysis

    Burla MM, Chater RC, … senior author Haber R

  12. 71352

    Efficacy of izokibep, a novel interleukin-17A inhibitor, in moderate to severe hidradenitis suppurativa: Week 32 results from a randomized, double-blind, placebo-controlled, multicenter, phase 3 study

    Papp KA, Bechara FG, … senior author Kimball AB

  13. 71368

    Unmet needs in atopic dermatitis (AD) treated with current biologic therapies: results from an international cross-sectional cohort study

    Chovatiya R, Dillon P, … senior author Irvine AD

  14. 71903

    Long-Term Real-World Effectiveness, Safety and Retention of Guselkumab in a Spanish Psoriasis Cohort: A Retrospective Study

    Bascón L, Muñoz-Santos C, Vidal AG

  15. 71981

    Evidence-Based Biologic Selection for Moderate-to-Severe Psoriasis in Patients with IBD and Heart Failure

    Tognaccini C, Osborne S, … senior author Wu J

  16. 72064

    Early secukinumab treatment within the window of opportunity: a systematic review of its potential as a disease modifying strategy in the management of psoriatic disease

    Conrad C, Lalazi B, … senior author García Ruiz de Morales JM

  17. 72091

    SPECTREM: Guselkumab Skin Clearance and Patient-Reported Outcome Results Across Skin and Joint Symptoms Through Week 48 in Low Body Surface Area, Moderate Plaque Psoriasis With at Least One Moderate High-Impact Site Involved

    Gold LS, Papp KA, … senior author Lebwohl MG

  18. 72124

    Real-World Use Patterns and Complications of Biologic Grafts in Mohs Micrographic Surgery: A Retrospective 10-Year Analysis

    Pitchford C, Talasila S, … senior author Tolkachjov S

  19. 72304

    Sequential Switching Between Ustekinumab Biosimilars in Psoriasis: Real-World Evidence of Clinical Interchangeability

    De Luca DA, Papara C, … senior author Thaçi D

  20. 72319

    Dupilumab Improves Itch- and Hive-Free Days in Patients With Chronic Spontaneous Urticaria

    Yosipovitch G, Ensina LF, … senior author Makhija M

  21. 72376

    Impact of Biologic and Oral Therapies on Systemic Inflammation in Psoriasis Measured by the Systemic Immune-Inflammation Index

    Johnsen N, Smart K, … senior author Armstrong A

  22. 72433

    Characterization of the IHS4 Response to Lutikizumab Treatment in Biologic-Naïve Patients With Moderate-to-Severe Hidradenitis Suppurativa (HS)

    Alhusayen R, Zouboulis CC, … senior author Kimball AB

  23. 72509

    Association of Dupilumab Use with Acute Care Utilization and Mortality Outcomes Among Patients with Cutaneous Immune-Related Adverse Events: A Global TriNetX Database Study

    Block B, Mehta J, Gulati N

  24. 72537

    Lebrikizumab from Skin to Airways: Comorbid Allergic Rhinitis in Patients with Atopic Dermatitis and the PREPARED-1 Perennial Allergic Rhinitis Trial Design

    Golant A, Casale T, … senior author Corren J

  25. 72602

    Real-world evidence of dupilumab’s efficacy in reducing autoantibodies to bullous pemphigoid antigens

    Karpoff K, Patel A, … senior author Lebwohl M

  26. 72640

    Enhanced effectiveness of guselkumab as first-line biologic therapy in psoriasis: real-world results over 84 weeks from the G-REAL study

    Gerdes S, Hoffmann M, … senior author von Kiedrowski R

  27. 72665

    Effectiveness, Safety, and Reduction of Systemic Inflammatory Response in Patients with Plaque Psoriasis Treated with Bimekizumab: A Real-Life Case Series

    Carrasco-Muñoz J, Albert-Cobo I, … senior author García-Fernández L

  28. 72716

    Guselkumab shows better long-term effectiveness and drug survival compared to secukinumab through 84 weeks in patients with moderate-to-severe plaque psoriasis - Results from the German non-interventional G-REAL study

    von Kiedrowski R, Gerdes S, … senior author Hoffmann M

  29. 72740

    Real-World Effectiveness of Upadacitinib for Atopic Dermatitis Across Body Regions by Prior Biologic Exposure in the AD-VISE Study

    Gooderham M, Lang C, … senior author Ameen A

  30. 72744

    Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: A Post-Hoc Analysis of UNCOVER-3

    Armstrong A, Merola J, … senior author Pinter A

  31. 72762

    Efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis affecting the nails: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b trial

    Yamauchi PS, Kerdel F, … senior author Sofen HL

  32. 72814

    Long-term (≥3 year) efficacy and safety of subcutaneous spesolimab for treatment of generalized pustular psoriasis: results from the EFFISAYIL program

    Gudjonsson JE, Navarini AA, … senior author Morita A

  33. 72888

    APEX: Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis by Participant Baseline Characteristics

    Mease PJ, Ritchlin CT, … senior author Rahman P

  34. 72909

    Bimekizumab durability of response through 4 years in patients with plaque psoriasis who stopped and re-started treatment

    Griffiths CEM, Costanzo A, … senior author Han G

  35. 72952

    Brodalumab Delivers 8 Years of Safety Success

    Lebwohl M, Martin G, … senior author Strober B

  36. 73014

    Real-world tildrakizumab persistence in the US by biologic experience and insurance coverage in the PPD CorEvitas Psoriasis Registry

    Lockshin B, Beeghly A, … senior author Prajapati VH

  37. 73017

    Regional differences in patient characteristics among US biologic initiators from the PPD CorEvitas Psoriasis Registry

    Prajapati VH, Blachley T, … senior author Lockshin B

  38. 73044

    Combination Biologic Therapy in Severe, Refractory Hidradenitis Suppurativa: Safety and Early Clinical Outcomes

    Bastian E, Naik H

  39. 73105

    Dupilumab Improves Itch, Pain, and Sleep in Epidermolysis Bullosa and Ichthyosis: 1-Year Interim Data

    Bai I, Yousif R, … senior author Paller A

  40. 73132

    Beyond Trial-and-Error: Mechanism-Guided Use of Biologics in Scalp Psoriasis

    Patra P

  41. 73136

    Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules. BIOBADADERM Registry

    Olivares-Guerrero M, Jiménez-Sánchez A, … senior author Daudén E

  42. 73163

    Representation of Race and Ethnicity in Randomized Control Trials of Biologic Therapies for Psoriasis: A Scoping Review

    Garcia S, Bosch L, … senior author Riley J

  43. 73230

    Bimekizumab efficacy by patient subgroups in moderate to severe hidradenitis suppurativa: 3-year phase 3 results from BE HEARD EXT

    Sayed CJ, Porter ML, … senior author Kokolakis G

  44. 73330

    Stabilization of acute alopecia areata flares with short-term omalizumab in patients relapsing during JAK inhibitor treatment

    Lin J, Wang Q, … senior author Wu W

  45. 73341

    Effect of Risankizumab Versus Deucravacitinib on Psoriasis-Related Symptoms and Quality of Life in Patients With Moderate Plaque Psoriasis: Results From the IMMpactful Trial at Week 16

    Soung J, Magnolo N, … senior author Warren RB

  46. 73380

    Bimekizumab pharmacokinetics, safety, and efficacy in adolescents with moderate to severe plaque psoriasis: Data from the initial treatment period of the open-label BE CONNECTED phase 2 study

    Paller A, Szepietowski JC, … senior author Pinter A

  47. 73392

    Bimekizumab time to clinical response and achievement of clinically meaningful improvement thresholds in Chinese patients with psoriasis from the BE SHINING phase 3 trial

    Cai L, Man XY, … senior author Zhang J

  48. 73400

    Bimekizumab in Hidradenitis Suppurativa: Insights from Real-World Clinical Practice

    González LA, Romero IV, … senior author Barrios ML

  49. 73455

    Quantifying Delays in Initiation of Biologic Therapy for Pyoderma Gangrenosum

    Shea M, Vague M, … senior author Ortega-Loayza A

  50. 73456

    Patient-Level Persistence of On-Treatment Remission With Guselkumab: Pooled Results From VOYAGE 1 and VOYAGE 2 Participants With Moderate-to-Severe Plaque Psoriasis

    Tada Y, Foley P, … senior author Langley RG